[Diagnosis and management of severe adverse events occurring during BCG therapy for non-muscle invasive bladder cancer (NMIBC)].

Abstract

BCG therapy, which is the standard treatment for non-muscle invasive bladder tumours with high risk of recurrence and progression, has potential life-threatening adverse effects (AEs). Rapid deterioration of general condition in a patient with history of bladder tumour should question about an ongoing treatment with BCG and specify the date of the last… (More)
DOI: 10.1016/j.lpm.2012.10.017

Topics

1 Figure or Table

Slides referencing similar topics